Top-Rated StocksTop-RatedNASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis $18.35 -0.17 (-0.92%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$18.22▼$19.3350-Day Range$14.40▼$27.2852-Week Range$9.44▼$36.25Volume760,866 shsAverage Volume960,464 shsMarket Capitalization$948.75 millionP/E RatioN/ADividend YieldN/APrice Target$43.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get 4D Molecular Therapeutics alerts: Email Address 4D Molecular Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside137.7% Upside$43.63 Price TargetShort InterestBearish20.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 11 Articles This WeekInsider TradingSelling Shares$821,939 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.98) to ($3.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector754th out of 936 stocksBiological Products, Except Diagnostic Industry129th out of 154 stocks 3.5 Analyst's Opinion Consensus Rating4D Molecular Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about 4D Molecular Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.00% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 4.55%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FDMT. Previous Next 2.8 News and Social Media Coverage News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for 4D Molecular Therapeutics this week, compared to 3 articles on an average week.Search Interest18 people have searched for FDMT on MarketBeat in the last 30 days. This is an increase of 1,700% compared to the previous 30 days.MarketBeat Follows6 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $821,939.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of 4D Molecular Therapeutics is held by insiders.Percentage Held by Institutions99.27% of the stock of 4D Molecular Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 4D Molecular Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.98) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 4D Molecular Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Read More FDMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FDMT Stock News HeadlinesJuly 19, 2024 | insidertrades.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $47,442.50 in StockJuly 16, 2024 | insidertrades.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 1,996 SharesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 14, 2024 | insidertrades.comDavid Kirn Sells 12,923 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockJuly 4, 2024 | insidertrades.comInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 4,248 Shares of StockJune 27, 2024 | insidertrades.comDavid Kirn Sells 12,930 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) StockJuly 25 at 4:00 PM | globenewswire.com4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 23 at 5:29 AM | americanbankingnews.com4D Molecular Therapeutics' (FDMT) "Outperform" Rating Reaffirmed at Royal Bank of CanadaJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 22, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)July 22, 2024 | prnewswire.comFDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmJuly 21, 2024 | businesswire.com4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 20, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00July 19, 2024 | globenewswire.com4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJuly 19, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from Chardan CapitalJuly 19, 2024 | americanbankingnews.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Down 6.8% After Insider SellingJuly 17, 2024 | seekingalpha.com4D Molecular Therapeutics, Inc. (FDMT) Special Call TranscriptJuly 17, 2024 | globenewswire.com4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical ActivitySee More Headlines Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FDMT CUSIPN/A CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$43.63 High Stock Price Target$81.00 Low Stock Price Target$24.00 Potential Upside/Downside+130.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,840,000.00 Net MarginsN/A Pretax Margin-511.23% Return on Equity-26.75% Return on Assets-24.84% Debt Debt-to-Equity RatioN/A Current Ratio32.65 Quick Ratio32.65 Sales & Book Value Annual Sales$20.72 million Price / Sales47.16 Cash FlowN/A Price / Cash FlowN/A Book Value$7.20 per share Price / Book2.63Miscellaneous Outstanding Shares51,700,000Free Float47,929,000Market Cap$977.13 million OptionableOptionable Beta2.83 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. John F. Milligan Ph.D. (Age 63)Executive Chairman Comp: $150kDr. David H. Kirn M.D. (Age 61)Co-Founder, CEO & Director Comp: $1.01MDr. Fariborz Kamal Ph.D. (Age 61)President & COO Comp: $786.2kDr. Noriyuki Kasahara M.D. (Age 61)Ph.D., Chief Scientific Officer Comp: $201.29kDr. Robert Y. Kim M.B.A. (Age 63)M.D., Chief Medical Officer Comp: $704.84kMs. Theresa Janke (Age 49)Co-Founder & Chief of Staff Comp: $652.32kMr. Uneek Mehra (Age 52)Chief Financial & Business Officer Dr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal Officer & Corporate Secretary Dr. An Song Ph.D.Chief Development OfficerDr. Alan H. Cohen FAAAAI (Age 63)FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology More ExecutivesKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXMorphicNASDAQ:MORFMorphoSysNASDAQ:MORBausch Health CompaniesNYSE:BHCSpringWorks TherapeuticsNASDAQ:SWTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 38,015 shares on 7/26/2024Ownership: 0.328%Nisa Investment Advisors LLCBought 95,041 shares on 7/20/2024Ownership: 0.187%Assenagon Asset Management S.A.Bought 25,711 shares on 7/18/2024Ownership: 0.883%Scott BizilySold 1,750 sharesTotal: $47,442.50 ($27.11/share)Scott BizilySold 1,996 sharesTotal: $49,900.00 ($25.00/share)View All Insider TransactionsView All Institutional Transactions FDMT Stock Analysis - Frequently Asked Questions How have FDMT shares performed this year? 4D Molecular Therapeutics' stock was trading at $20.26 at the beginning of 2024. Since then, FDMT stock has decreased by 9.4% and is now trading at $18.35. View the best growth stocks for 2024 here. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) posted its earnings results on Thursday, May, 9th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.07. The firm earned $0.03 million during the quarter, compared to analysts' expectations of $1.44 million. When did 4D Molecular Therapeutics IPO? 4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager. Who are 4D Molecular Therapeutics' major shareholders? 4D Molecular Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.88%), Bank of New York Mellon Corp (0.33%) and Nisa Investment Advisors LLC (0.19%). Insiders that own company stock include Global Investors Lp Viking, David Kirn, Scott Bizily, Robert Young Kim and David Schaffer. View institutional ownership trends. How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FDMT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
